Compare GRF & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | BMEA |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 42.4M |
| IPO Year | N/A | 2021 |
| Metric | GRF | BMEA |
|---|---|---|
| Price | $10.14 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.17 |
| AVG Volume (30 Days) | 4.2K | ★ 983.5K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.50 | $0.45 |
| 52 Week High | $11.85 | $2.24 |
| Indicator | GRF | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 38.28 |
| Support Level | $9.72 | $0.55 |
| Resistance Level | $10.52 | $0.69 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 19.57 | 48.35 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.